

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL 8 - 14 December 2025



#### **Private petrochemical producers set for robust growth**

China's vast private petroleum and chemical sector is positioned for robust and broad growth, driven by its aggressive pivot from traditional processing toward high-end specialization across the value chain. China's vast private petroleum and chemical sector have witnessed notable progress, with its top 100 companies generating more than 5.67 trillion yuan (€676 billion) in revenue last year. ([China Daily](#))

#### **Mexico Initiates Interim Review Investigation into Antidumping Duties on Chinese Products**

On November 21, 2025, the Mexican Ministry of Economy announced that, in response to an application from the Mexican company Convertidora Industrial, S.A.B. de C.V., it has initiated an interim review investigation into antidumping duties on metal-film plastic balloons originating from China to examine whether adjustments to the existing antidumping duties are necessary. ([Official Mexican Gazette](#))

#### **Vietnam Initiates Sunset Review Investigation into Anti-dumping Duty on Sorbitol from China**

On November 20, 2025, the Vietnamese Ministry of Industry and Trade issued Announcement No. 3377/QD-BCT, stating that, at the request of Vietnamese producers, it has initiated a sunset review investigation into anti-dumping duties on sorbitol originating from China, India, and Indonesia. The Vietnamese tariff codes for the products involved are 2905.44.00 and 3824.60.00. ([Website of the Trade and Defense Department of the Vietnamese Ministry of Industry and Trade](#))

#### **China's biopharma sector enters 'innovation 2.0' era**

China ranks as the world's second-biggest pharmaceutical market. It's also the second-largest producer of new molecular entities. Those grabbed 18% of global first launches, according to Clarivate's recent report. Clarivate calls this move from "Innovation 1.0" to "Innovation 2.0." Chinese firms are now leading on cutting-edge work that big global players scramble to buy. ([Drug Discovery & Development](#))

#### **China pharmaceutical highlights from PharmaBoardroom**

China pharmaceutical highlights from PharmaBoardroom include, Biokin filing China's first EGFR/HER3 bispecific ADC NDA, Novartis gaining NMPA approval for remibrutinib in urticaria, Innovent's PECONDLE® approved as China's first IL-23p19 antibody for psoriasis and IASO Bio's Fucaso approved as China's first CAR-T therapy in Hong Kong. ([PharmaBoardroom](#))